Makes animal-health products — medicated feed additives, vaccines and nutritional specialties for livestock and pets.
Makes animal-health products — medicated feed additives, vaccines and nutritional specialties for livestock and pets.
Sells to producers of chickens, pigs and cattle through feed companies and distributors, with medicated feed additives, which prevent disease in herds, the largest line, and poultry the largest customer group. The Bendheim family keeps control through a separate class of shares.
Moat: narrow (regulatory licence, scale, distribution). Registered animal-drug approvals and an established livestock distribution network limit new entrants.
Headquarters: Teaneck, New Jersey, US · Founded: 1954 · Employees: 2,605
Size Phibro Animal Health (PAHC) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.44B, the 1994th largest of 3,085 United States companies the cockpit tracks. Shares closed at $35.57 on 18 Nov 2026.
Performance Over six months the shares gained 5.2%, against -14.9% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 10.1% over the last twelve months (peer median +9.2%); the operating margin is 13.2% (peer median 9.4%).
Valuation It trades at 9.9× forward earnings against a peer median of 23.2× (2nd cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -19 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.7 points above its cost of capital (6.6% WACC).
Short interest Short interest is 4.8% of the free float (30 Oct 2026).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $1.54B | $1.52B | $1.30B | $1.02B | $978M |
| Revenue growth | — | +17% | +27% | +4% | — |
| Gross profit | $519M | $510M | $391M | $312M | $299M |
| EBITDA | $255M | $252M | $167M | $98.6M | $114M |
| Net income | $103M | $99.7M | $48.3M | $2.42M | $32.6M |
| Free cash flow | $21.7M | $9.87M | $41.8M | $46.4M | -$38.5M |
| Capital expenditure | $64.1M | $59.1M | $38.3M | $41.2M | $51.8M |
| Total debt | $789M | $789M | $762M | $525M | $510M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Phibro Animal Health PAHC | $1.44B | +5% | +10% | 13% | 9.9× | -6.4% |
| Zoetis ZTS | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% |
| Elanco Animal Health ELAN | $13.3B | +28% | +12% | 8% | 21.5× | 32.9% |
| Merck & MRK | $340B | +23% | +5% | 18% | 16.4× | 8.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PAHC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.3% | -3.9% | 8th lowest of 21 |
| 6-month return | +5.2% | -14.9% | 4th highest of 21 |
| Distance from 52-week high | -40.8% | -40.7% | 11th highest of 21 |
| Revenue growth (TTM) | +10.1% | +9.2% | 10th highest of 20 |
| Operating margin | 13.2% | 9.4% | 7th highest of 20 |
| Forward P/E | 9.9× | 23.2× | 2nd cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -6.4% | -0.5% | 4th least demanding of 11 |
| Growth delivered (Del g) | +12.7% | +16.6% | 5th lowest of 11 |
| Hurdle (Req g minus delivered) | -19.1 pp | -7.9 pp | 3rd least demanding of 11 |
| ROIC minus cost of capital | +7.7 pp | -1.8 pp | 4th highest of 20 |
| EV / EBITDA | 8.4× | 17.6× | 2nd cheapest of 5 |
| Net debt / EBITDA | 2.8× | 0.1× | 2nd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 9.9× | -6.4% | +12.7% |
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 27.2× | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | n/a | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 23.2× | 31.0% | +16.6% |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 7.9× | -18.1% | +7.0% |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 58.9× | 36.3% | +16.6% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | n/a | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 12.1× | -9.6% | +4.6% |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | n/a | n/a | n/a |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | n/a | n/a | n/a |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | n/a | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 13.0× | 3.9% | +22.8% |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | n/a | 10.2% | +18.1% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 25.6× | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 48.6× | 25.9% | +23.1% |